Noven Tries To Block Watson's Generic Daytrana
Noven Pharmaceuticals Inc. on Thursday filed a patent infringement suit seeking to stop Watson Pharmaceuticals Inc. from marketing generic versions of Daytrana, Noven's patch treatment for children with attention deficit hyperactivity...To view the full article, register now.
Already a subscriber? Click here to view full article